共 50 条
- [1] A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Schellens, J. H.Leijen, S.Shapiro, G. I.Pavlick, A. C.Tibes, R.O'Day, S. J.Demuth, T.Viscusi, J.Xu, Y.Oza, A. M.
- [2] A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Leijen, S.Schellens, J. H.Shapiro, G.Pavlick, A. C.Tibes, R.Demuth, T.Viscusi, J.Cheng, J. D.Xu, Y.Oza, A. M.
- [3] Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4371 - +Leijen, Suzannevan Geel, Robin M. J. M.Pavlick, Anna C.Tibes, RaoulRosen, LeeRazak, Albiruni R. AbdulLam, RaymondDemuth, TimRose, ShelonitdaLee, Mark A.Freshwater, TomokoShumway, StuartLiang, Li WenOza, Amit M.Schellens, Jan H. M.Shapiro, Geoffrey I.
- [4] Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3409 - +Do, KhanhWilsker, DeborahJi, JiupingZlott, JenniferFreshwater, TomokoKinders, Robert J.Collins, JerryChen, Alice P.Doroshow, James H.Kummar, Shivaani
- [5] Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775EJC SUPPLEMENTS, 2010, 8 (07): : 202 - 202Cheng, J. D.Tibes, R.Schellens, J. H.Shapiro, G. I.Pavlick, A. C.Oza, A. M.Xu, Y.Song, Y.Lam, R. L. H.Demuth, T.
- [6] Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Do, Khanh TuWilsker, DeborahBalasubramanian, PriyaZlott, JenniferJeong, WoondongLawrence, Scott M.Kinders, Robert J.Collins, JerryChen, Alice P.Doroshow, James H.Kummar, Shivaani
- [7] Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitorJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Rose, ShelonitdaCheng, Jonathan D.Viscusi, JohnnyIannone, RobertSchellens, Jan H. M.Leijen, SuzanneShapiro, GeoffreyPavlick, Anna C.Oza, Amit M.Rosen, Lee S.Tosolini, AlessandraLam, RaymondDemuth, Tim
- [8] The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase lb studyMOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Bang, Yung-JueDe Souza, PaulKim, Sang-WeLickliter, JasonNaito, YoichiPark, KeunchilKumar, SanjeevMugundu, Ganesh M.Kato, Hidenori
- [9] Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85SJones, S. F.Plummer, E. R.Burris, H. A.Razak, A. R.Meluch, A. A.Bowen, C. J.Williams, D. H.Hodge, J. P.Dar, M. M.Calvert, A. H.
- [10] Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1060 - +Daud, Adil I.Ashworth, Michelle T.Strosberg, JonathanGoldman, Jonathan W.Mendelson, DavidSpringett, GregoryVenook, Alan P.Loechner, SabineRosen, Lee S.Shanahan, FrancesParry, DavidShumway, StuartGrabowsky, Jennifer A.Freshwater, TomokoSorge, ChristopherKang, Soonmo PeterIsaacs, RandiMunster, Pamela N.